Semaglutide vs Wegovy: Are They the Same Medication?
Confused about semaglutide vs Wegovy? They contain the same active ingredient but differ in dose, formulation, and FDA approval. Here's everything explained.
More on GLP-1 Treatment Comparisons
Ozempic vs Mounjaro: Full Comparison
Head-to-head breakdown of Ozempic and Mounjaro for weight loss and diabetes.
Compounded Semaglutide vs Wegovy
Is compounded semaglutide as effective as brand-name Wegovy?
Semaglutide vs Ozempic vs Wegovy Explained
Clear guide to the naming confusion around semaglutide products.
Best Weight Loss Medication 2026
Ranking and comparing all major prescription weight loss options in 2026.
The Naming Confusion Explained: Generic vs Brand Name
One of the most common sources of confusion in GLP-1 treatment is the relationship between "semaglutide," "Wegovy," and "Ozempic." These names refer to the same active drug molecule, but in different commercial contexts. Understanding the distinction is essential for making informed treatment decisions.
The Semaglutide Family: Quick Reference
Think of it this way: "semaglutide" is to "Wegovy/Ozempic" as "ibuprofen" is to "Advil/Motrin." Same active ingredient, different product names, doses, and approved uses.
Wegovy vs Ozempic: Same Drug, Different Products
Although both products are made by Novo Nordisk using the same active molecule, Wegovy and Ozempic are meaningfully different pharmaceutical products in practice.
Wegovy (Semaglutide for Obesity)
- Dose: 0.25mg → 2.4mg (over 16 weeks)
- Indication: Chronic weight management
- FDA approval: June 2021
- Clinical trial: STEP program (15% avg loss)
- List price: ~$1,350/month
- Insurance: Variable — obesity coverage limited
Ozempic (Semaglutide for Diabetes)
- Dose: 0.25mg → 1mg (or 2mg)
- Indication: Type 2 diabetes + CV risk reduction
- FDA approval: December 2017
- Clinical trial: SUSTAIN program (10% avg loss)
- List price: ~$900–$970/month
- Insurance: Usually well-covered for T2D
An important practical note: Ozempic is frequently prescribed off-label for weight loss (i.e., to people without diabetes). While it produces less weight loss than Wegovy (due to lower maximum dose), it is still an effective weight loss medication, and many providers prescribe it when Wegovy is unavailable or unaffordable.
Compounded Semaglutide: The Third Option
A third category of semaglutide products has become widely available: compounded semaglutide produced by FDA-registered 503B outsourcing facilities and 503A compounding pharmacies.
Compounded semaglutide is legally permitted when the FDA has declared Wegovy or Ozempic to be in shortage. During shortage periods (which occurred throughout 2022–2024 and have fluctuated since), compounding pharmacies can legally prepare and dispense semaglutide formulations.
Compounded Semaglutide Key Facts
- Active ingredient: Same semaglutide molecule as Wegovy/Ozempic
- Formulation: Typically vials for self-injection (not auto-inject pens)
- Cost: $99–$269/month (Trimi pricing), vs $1,350 for brand-name Wegovy
- Regulation: FDA-registered 503B facilities; not FDA-approved as a finished product
- Availability: Dependent on FDA shortage designation at time of prescription
- Not covered by insurance as a compounded product
For a detailed comparison of compounded vs brand-name options, see our article on compounded semaglutide vs Wegovy.
Full Cost Comparison: All Semaglutide Options
Cost is one of the primary drivers of which semaglutide product a patient ends up using. Here is the full pricing landscape:
Wegovy (brand, 2.4mg weekly)
~$1,350/month list price~$0–$50/month with qualifying insurance
Manufacturer savings card available (up to $500 off/month)
Ozempic (brand, 1–2mg weekly)
~$900–$970/month list priceOften well-covered for T2D patients
Frequently prescribed off-label for weight loss
Compounded semaglutide (e.g., Trimi)
$99–$269/monthNot covered by insurance (cash pay)
Same active ingredient; available during FDA shortage periods
Rybelsus (oral, 7–14mg daily)
~$850/month list priceTypically covered for T2D
Lower efficacy for weight loss; requires fasting before dose
How to Decide Which Semaglutide Product Is Right for You
The decision tree is primarily practical: insurance coverage and cost drive the real-world choice for most patients.
You have type 2 diabetes with good insurance
Start with Ozempic — typically well-covered, proven CV and glucose benefits
Action: Ask your endocrinologist or PCP about Ozempic coverage
You have obesity without diabetes, insurance covers Wegovy
Wegovy 2.4mg is the FDA-approved, highest-dose option with the best weight loss data
Action: Verify your specific plan's coverage and prior authorization requirements
No insurance coverage and cost is a concern
Compounded semaglutide via telehealth (Trimi, etc.) at $99–$269/month offers the same active ingredient
Action: Verify FDA shortage status at time of prescribing to confirm legality
Maximum weight loss is the goal and cost is not a barrier
Consider tirzepatide (Zepbound/Mounjaro) — produces 20% vs 15% average weight loss
Action: Discuss tirzepatide with your provider; compare to semaglutide options
For a broader comparison that includes tirzepatide options, see our best weight loss medication guide for 2026.
Important: All Semaglutide Products Share the Same Safety Profile
Regardless of whether you use Wegovy, Ozempic, or compounded semaglutide, the active molecule is the same — and so is the safety profile. Key considerations that apply to all semaglutide products:
- Contraindicated in pregnancy — discontinue at least 2 months before attempting conception
- Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
- Risk of pancreatitis — seek medical attention for severe, persistent abdominal pain
- GI side effects (nausea, vomiting, diarrhea) are common during dose escalation; usually resolve within 4–8 weeks
- Dose reduction is appropriate if side effects are intolerable — do not self-discontinue without consulting your provider
Frequently Asked Questions
Is semaglutide the same as Wegovy?
Yes and no. Semaglutide is the generic (active ingredient) name of the medication. Wegovy is one brand name for semaglutide — specifically the formulation approved by the FDA for chronic weight management at a dose of 2.4mg weekly. Ozempic is another brand name for semaglutide, but at a lower dose (up to 1mg or 2mg weekly) and approved for type 2 diabetes. The active molecule is identical; what differs is the dose, FDA-approved indication, and manufacturer packaging.
What is the difference between Wegovy and Ozempic?
Both Wegovy and Ozempic are brand-name formulations of semaglutide made by Novo Nordisk. Key differences: Wegovy is dosed up to 2.4mg weekly and FDA-approved for obesity/chronic weight management. Ozempic is dosed up to 2mg weekly and FDA-approved for type 2 diabetes and cardiovascular risk reduction. Wegovy comes in a different pen device. Despite the different names, the active ingredient (semaglutide) is chemically identical in both.
What is compounded semaglutide and is it the same as Wegovy?
Compounded semaglutide is a version of semaglutide manufactured by FDA-registered compounding pharmacies rather than Novo Nordisk. It contains the same active molecule (semaglutide) but may come in different formulations (vials for subcutaneous injection vs. auto-inject pens), at various concentrations, and at substantially lower cost ($99–$269/month vs ~$1,350/month for Wegovy). Compounded semaglutide is legal when produced during an FDA-declared drug shortage. It is not FDA-approved as a finished drug product, unlike Wegovy.
Why does Wegovy cost more than Ozempic?
Wegovy typically costs more than Ozempic despite containing the same active ingredient due to higher doses (requiring more active ingredient per pen), different pen device technology, and the obesity indication carrying a different pricing structure. Ozempic often has better insurance coverage because diabetes drugs are more consistently covered than obesity drugs. Ozempic list price is approximately $900–$970/month vs Wegovy at approximately $1,350/month, though both vary significantly based on insurance.
Can I use Ozempic for weight loss instead of Wegovy?
Many people do use Ozempic off-label for weight loss, and clinically it produces meaningful weight loss results (approximately 10% at 1mg vs 15% at 2.4mg Wegovy). However, Ozempic maxes out at 2mg vs Wegovy's 2.4mg, so the maximum dose — and maximum weight loss potential — is slightly lower. Ozempic is not FDA-approved for obesity, meaning some insurance plans will not cover it for weight loss. Prescribers may still prescribe it off-label.
Which should I choose: Wegovy, Ozempic, or compounded semaglutide?
The practical decision depends primarily on cost and insurance coverage. If you have insurance covering Wegovy for obesity, that offers the full FDA-approved 2.4mg dose with the most clinical trial data and device support. If you have type 2 diabetes with Ozempic coverage, that may be the best insured option. For patients without insurance coverage or with high out-of-pocket costs, compounded semaglutide at $99–$269/month offers the same active ingredient at a fraction of the cost. Discuss with your prescriber what is available in your situation.
Is there a generic semaglutide available in 2026?
As of 2026, there is no FDA-approved generic semaglutide (i.e., a generic drug application [ANDA] approved by FDA). Novo Nordisk's patents on the semaglutide molecule and delivery devices extend through the late 2020s. Compounded semaglutide from 503B outsourcing facilities is the current alternative for cost-conscious patients. FDA-approved generic semaglutide would require patent expiry or challenge, likely not before 2030.
Sources & References
- FDA. "FDA Approves New Drug Treatment for Chronic Weight Management." FDA News Release. June 4, 2021. (Wegovy approval)
- FDA. "FDA Approves New Drug Treatment for Type 2 Diabetes." FDA News Release. December 5, 2017. (Ozempic approval)
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021;384:989–1002. (STEP-1)
- Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." NEJM. 2016;375:1834–1844. (SUSTAIN-6)
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." NEJM. 2023;389:2221–2232. (SELECT trial)
- FDA. "Drug Shortage Database — Semaglutide." FDA Drug Shortages. Updated 2024–2025.
- Davies M, et al. "Efficacy of Liraglutide for Weight Management — A Systematic Review." Obesity Reviews. 2021.